One development chain, different quality questions

GxP is an umbrella term for quality practices. GLP concerns the organisation and traceability of specified nonclinical safety data; GMP concerns controlled manufacture of a product; GCP concerns ethical and reliable research involving people.

The exact requirement depends on the product, stage, jurisdiction and purpose of the work. Expert review therefore starts with context rather than a generic certificate checklist.

GCP: participants, protocol and reliable data

ICH E6(R3) describes Good Clinical Practice as an international ethical, scientific and quality standard for trials involving human participants. It emphasises participant rights, safety and well-being, informed consent, qualified teams, adequate resources, quality management and interpretable results.

GCP is not limited to the investigator. Responsibilities extend across sponsors, investigators, ethics committees and other functions; computerised systems also require security, access control, validation and traceability.

GLP: quality in nonclinical safety studies

The OECD Principles of GLP provide an organisational framework for planning, performing, monitoring, recording, archiving and reporting nonclinical health and environmental safety studies. Study plans, roles, procedures, equipment, raw data, quality assurance and archives all matter.

GLP does not mean that every laboratory experiment follows the same regulated pattern. Discovery work, mechanistic studies and regulatory safety studies can have different purposes and requirements.

GMP: reproducible product manufacture

Good Manufacturing Practice aims to ensure that medicinal products are consistently produced and controlled to the required quality standards. The system covers people, facilities, documentation, materials, processes, testing, deviations and batch release.

GMP reduces the risk of product inconsistency. It does not answer the separate clinical questions of benefit, risk and place in therapy.

Joining the standards in one programme

A development programme connects product characterisation and nonclinical evidence, suitable manufacturing quality, clinical strategy, ethics and regulatory review, trial conduct and analysis.

Expertise is valuable when it identifies gaps between these stages early: weak traceability, non-comparable material, an unclear intended use, a poor link between risk and evidence, or an unprepared clinical process.

Quick answers

Frequently asked questions

Is a study GLP-compliant because it was performed in a good laboratory?

No. Laboratory quality alone does not establish compliance with the applicable GLP framework; the complete documented system and scope matter.

Does GMP mean that a medicine is effective?

No. GMP concerns manufacturing and quality control. Clinical benefit and risk require a separate evidence programme.

Which standard is most important?

They answer different questions. Mature development requires the applicable quality systems to work coherently across the product lifecycle.

Evidence base

Primary and authoritative sources

Use the linked source documents for professional or current interpretation.